Serum folate receptor alpha as a biomarker for epithelial ovarian cancer
| Project/Area Number |
25861504
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 葉酸受容体アルファ / 卵巣がん / バイオマーカー / 標的治療 / 予後 / 診断マーカー / コンパニオン診断薬 |
|---|
| Outline of Final Research Achievements |
Folate receptor alpha (FRA) is a GPI-anchored glycoprotein. High expression of FRA is observed in epithelial malignant tumors, including ovarian cancer. We prospectively investigated the levels of sFRA in patients clinically suspected of having malignant ovarian tumors. A total of 231 patients were analyzed for sFRA as well as tumor expression of FRA by immunohistochemistry. High sFRA was predominantly observed in epithelial ovarian cancer patients, but not in patients with benign or borderline gynecological disease or metastatic ovarian tumors from advanced colorectal cancers. Levels of sFRA was highly correlated to clinical stage, tumor grade and histological type and demonstrated superior accuracy for the detection of ovarian cancer than did serum CA125. Finally, tumor FRA expression status was strongly correlated with sFRA levels. Taken together these data suggest sFRA might be a useful non-invasive serum biomarkers for future clinical trials assessing FRA-targeted therapy.
|
Report
(3 results)
Research Products
(3 results)
